BeOne Medicines (BEIGF) Liabilities and Shareholders Equity (2015 - 2026)

BeOne Medicines (BEIGF) has 12 years of Liabilities and Shareholders Equity data on file, last reported at $8.6 billion in Q1 2026.

• Liabilities and Shareholders Equity for Q1 2026 came in at $8.6 billion, up 46.43% year-over-year; the trailing twelve-month figure through Mar 2026 was $30.7 billion (up 31.61% YoY), and the FY2025 annual result was $8.2 billion, up 38.3% from the prior year.
• Liabilities and Shareholders Equity rose to $8.6 billion in Q1 2026 per BEIGF's latest filing, from $8.2 billion in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $8.6 billion in Q1 2026 and troughed at $5.5 billion in Q4 2022.
• A 5-year average of $6.5 billion and a median of $5.9 billion in 2024 frame the typical range for Liabilities and Shareholders Equity.
• The sharpest annual moves came in 2022 and 2026: Liabilities and Shareholders Equity slumped 35.78% in 2022, then jumped 46.43% in 2026.
• A 5-year view of Liabilities and Shareholders Equity shows it stood at $5.5 billion in 2022, then grew by 5.91% to $5.8 billion in 2023, then increased by 1.99% to $5.9 billion in 2024, then surged by 38.3% to $8.2 billion in 2025, then increased by 4.46% to $8.6 billion in 2026.
• Business Quant data shows BEIGF's Liabilities and Shareholders Equity at $8.6 billion in Q1 2026, $8.2 billion in Q4 2025, and $7.6 billion in Q3 2025.